Clinical Trial Update: Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Becotatug Vedotin for locally advanced nasopharyngeal carcinoma with suboptimal response to induction chemotherapy, in combi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Becotatug Vedotin

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Cancinoma (NPC) | Phase 2 | Status: RECRUITING